Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J (2015) 2.25

Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation (2014) 2.24

Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace (2013) 1.53

Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients. Europace (2013) 1.40

Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. J Am Coll Cardiol (2016) 1.39

Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. Br J Gen Pract (2015) 1.16

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J (2016) 1.14

An update on the prognosis of patients with atrial fibrillation. Circulation (2012) 1.09

Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc (2015) 1.06

Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc (2015) 0.99

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One (2012) 0.99

European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol (2015) 0.99

CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatr Cardiol (2013) 0.96

Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in Sweden. BMJ Open (2013) 0.96

Anticoagulation in atrial fibrillation. BMJ (2014) 0.93

Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol (2015) 0.93

New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther (2014) 0.92

Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J (2014) 0.92

Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol (2014) 0.91

Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis (2013) 0.88

New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One (2013) 0.85

A Simple and Portable Algorithm for Identifying Atrial Fibrillation in the Electronic Medical Record. Am J Cardiol (2015) 0.85

Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol (2014) 0.85

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J (2016) 0.84

Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. PLoS One (2013) 0.83

Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. Drugs (2015) 0.82

Systemic Embolic Events (SEE) in Atrial Fibrillation: SEEing Embolic Risk More Clearly. Circulation (2015) 0.81

Warfarin use and incidence of stroke in Japanese hemodialysis patients with atrial fibrillation. Heart Vessels (2015) 0.80

Personalized approach to primary and secondary prevention of ischemic stroke. EPMA J (2014) 0.80

Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open Heart (2015) 0.80

Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study. PLoS One (2015) 0.79

Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making. Curr Med Res Opin (2015) 0.79

Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics (2014) 0.79

Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation? Am J Med (2013) 0.79

Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc (2014) 0.78

Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults--Ineffectiveness of Oral Anticoagulation Treatment with VKA. Biomed Res Int (2015) 0.78

Characterization of patients with atrial fibrillation not treated with oral anticoagulants. Scand J Prim Health Care (2014) 0.78

Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Tex Heart Inst J (2015) 0.78

Stroke and bleeding risk in atrial fibrillation. Korean Circ J (2014) 0.78

Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. Sci Rep (2016) 0.77

Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage. Neurology (2013) 0.77

Field Synopsis of the Role of Sex in Stroke Prediction Models. J Am Heart Assoc (2016) 0.77

Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation. Yonsei Med J (2014) 0.77

ACP Journal Club. Various risk stratification schemes predict ischemic stroke and bleeding in atrial fibrillation. Ann Intern Med (2012) 0.77

Treatment of Thyroid Dysfunctions Decreases the Risk of Cerebrovascular Events in Men but Not in Women: Results of the MONICA/KORA Cohort Study. PLoS One (2016) 0.76

Safety and Efficacy of Left Atrial Appendage Closure with the Amplatzer Cardiac Plug in Very High Stroke and Bleeding Risk Patients with Non-Valvular Atrial Fibrillation. Cardiol Ther (2015) 0.76

Comparison of the clinical features and outcomes in two age-groups of elderly patients with atrial fibrillation. Clin Interv Aging (2014) 0.76

Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimers Dement (2015) 0.76

Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. Pharmacotherapy (2015) 0.76

Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others? J Atr Fibrillation (2016) 0.75

Antithrombotic management of atrial fibrillation in the elderly. Med Clin North Am (2015) 0.75

Management of Atrial Fibrillation in Patients With Kidney Disease. J Atr Fibrillation (2014) 0.75

Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease. J Atr Fibrillation (2015) 0.75

Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice. Postgrad Med J (2013) 0.75

Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project. Sci Rep (2016) 0.75

Electrophysiology and heart rhythm disorders in older adults. J Geriatr Cardiol (2016) 0.75

Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. Adv Ther (2016) 0.75

The unmet need of stroke prevention in atrial fibrillation in the far East and South East Asia. Malays J Med Sci (2012) 0.75

Prediction of Thromboembolic Events in Heart Failure Patients in Sinus Rhythm: The Hong Kong Heart Failure Registry. PLoS One (2016) 0.75

Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care. Eur J Clin Pharmacol (2016) 0.75

Anemia: An Independent Predictor Of Adverse Outcomes In Older Patients With Atrial Fibrillation. J Atr Fibrillation (2016) 0.75

Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open (2017) 0.75

Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study. PLoS One (2015) 0.75

Emerging Tools for Stroke Prevention in Atrial Fibrillation. EBioMedicine (2016) 0.75

Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age. J Am Geriatr Soc (2016) 0.75

Putting risk prediction in atrial fibrillation into perspective. Eur Heart J (2012) 0.75

New oral anticoagulants - a practical guide. Kardiochir Torakochirurgia Pol (2015) 0.75

Stroke And Bleeding Risk Assessment: Where Are We Now? J Atr Fibrillation (2014) 0.75

Personalizing Bridging Anticoagulation in Patients with Nonvalvular Atrial Fibrillation-a Microsimulation Analysis. J Gen Intern Med (2017) 0.75

Potential use of NOACs in developing countries: pros and cons. Eur J Clin Pharmacol (2014) 0.75

Resumption of Anticoagulation After Intracranial Hemorrhage. Curr Treat Options Neurol (2017) 0.75

Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database. Drugs Aging (2017) 0.75

2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm (2017) 0.75

CHA2DS2-VASc Score: A Predictor of Thromboembolic Events and Mortality in Patients With an Implantable Monitoring Device Without Atrial Fibrillation. Mayo Clin Proc (2017) 0.75

Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA2DS2-VASc score of ≤1 and without anticoagulant therapy. Heart Vessels (2015) 0.75

Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation. CMAJ Open (2017) 0.75

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J (2012) 16.00

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J (2012) 12.36

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet (2007) 10.10

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace (2012) 7.33

Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60

Early cardiopulmonary resuscitation in out-of-hospital cardiac arrest. N Engl J Med (2015) 6.58

Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ (2011) 5.84

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Defibrillator implantation early after myocardial infarction. N Engl J Med (2009) 5.25

Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest (2013) 4.71

Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69

Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med (2010) 4.15

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01

Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet (2009) 3.83

Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol (2012) 3.49

Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation (2012) 3.47

Is atrial fibrillation an inflammatory disorder? Eur Heart J (2005) 3.33

Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ (2007) 3.30

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25

Survival is similar after standard treatment and chest compression only in out-of-hospital bystander cardiopulmonary resuscitation. Circulation (2007) 3.15

Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol (2013) 3.13

Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol (2013) 3.06

Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med (2014) 2.91

The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol (2008) 2.79

Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA (2011) 2.58

The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J (2003) 2.57

Anxiety, depression, and prognosis after myocardial infarction: is there a causal association? J Am Coll Cardiol (2003) 2.54

Mobile-phone dispatch of laypersons for CPR in out-of-hospital cardiac arrest. N Engl J Med (2015) 2.52

Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol (2005) 2.47

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J (2011) 2.40

Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol (2012) 2.32

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29

Advances in heart rate variability signal analysis: joint position statement by the e-Cardiology ESC Working Group and the European Heart Rhythm Association co-endorsed by the Asia Pacific Heart Rhythm Society. Europace (2015) 2.26

Improved survival after out-of-hospital cardiac arrest is associated with an increase in proportion of emergency crew--witnessed cases and bystander cardiopulmonary resuscitation. Circulation (2008) 2.25

Virchow's triad revisited. South Med J (2004) 2.23

Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost (2011) 2.22

Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation (2013) 2.22

Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation (2012) 2.20

Implantable cardioverter-defibrillator therapy before death: high risk for painful shocks at end of life. Circulation (2013) 2.20

Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace (2012) 2.19

Quality of life in patients with atrial fibrillation: a systematic review. Am J Med (2006) 2.17

Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J (2013) 2.17

Salt intake and Helicobacter pylori infection. J Hypertens (2004) 2.17

Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16

Compression-only CPR or standard CPR in out-of-hospital cardiac arrest. N Engl J Med (2010) 2.14

Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol (2007) 2.11

Ambulatory blood pressure monitoring in heart failure: a systematic review. Eur J Heart Fail (2005) 2.09

Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv (2012) 2.07

Indications for the use of diagnostic implantable and external ECG loop recorders. Europace (2009) 2.06

Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol (2013) 2.05

Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet (2010) 2.05

Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study). Stroke (2014) 2.05

Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost (2011) 2.01

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol (2012) 1.99

Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One (2013) 1.97

Ischemic stroke in South Asians: a review of the epidemiology, pathophysiology, and ethnicity-related clinical features. Stroke (2009) 1.97

Psychological factors in heart failure: a review of the literature. Arch Intern Med (2002) 1.96

The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia (2002) 1.96

Inflammation in atrial fibrillation. J Am Coll Cardiol (2012) 1.95

Asymptomatic hypoxia in a young pregnant lady--unusual presentation of atrial septal defect. Int J Cardiol (2009) 1.92

Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J (2006) 1.91

Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J (2007) 1.90

Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol (2008) 1.89

Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ (2007) 1.86

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84

Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest (2009) 1.84

The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J (2012) 1.82

Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J (2014) 1.81

Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J (2009) 1.79

The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost (2012) 1.78

A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. Chest (2011) 1.77

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol (2012) 1.76

Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis (2004) 1.76

Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost (2005) 1.73

The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol (2013) 1.72

Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res (2005) 1.71

Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol (2011) 1.70

Patients' understanding of anticoagulant therapy in a multiethnic population. J R Soc Med (2003) 1.69

Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation (2010) 1.68

Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol (2011) 1.67

Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) (2002) 1.67

Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J (2011) 1.67

'DNA' may not mean 'did not participate': a qualitative study of reasons for non-adherence at home- and centre-based cardiac rehabilitation. Fam Pract (2007) 1.66

Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation (2014) 1.65

Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost (2008) 1.65

Left ventricular systolic dysfunction in rheumatoid disease: an unrecognized burden? J Am Coll Cardiol (2006) 1.63

Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. J Thorac Cardiovasc Surg (2011) 1.61

Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ (2012) 1.61

Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. Am J Cardiol (2011) 1.59

Home-based cardiac rehabilitation compared with centre-based rehabilitation and usual care: a systematic review and meta-analysis. Int J Cardiol (2005) 1.58